Theravance Biopharma (TBPH) Operating Expenses (2013 - 2026)

Over the trailing twelve months to Jun 30, 2026, Theravance Biopharma reported Operating Expenses of $108.51 million, down 5.1% year-over-year; for FY2025, it came in at $111.07 million, down 0.2% from FY2024.

• Operating Expenses has declined in each of the last five years, with a five-year compound annual growth rate of -21.4% (FY2020 to FY2025).
• Going back by year, Operating Expenses was $111.33 million in FY2024 (-1.9%), $113.46 million in FY2023 (-20.8%), $143.3 million in FY2022 (-54.2%) and $313.1 million in FY2021 (-15.3%).
• The Q2 2026 figure represents the highest quarterly Operating Expenses since Q1 2025.
• Year-over-year, Operating Expenses increased in four of the last eight quarters, with growth averaging 2.8%.
• The fastest year-over-year change in Operating Expenses over five years came in Q4 2024 (growth of 17.4%), and the weakest in Q3 2022 (a decline of 67.7%).
• Business Quant data shows TBPH's Operating Expenses at $27.18 million (Q1 2026), $25.88 million (Q4 2025) and $26.45 million (Q3 2025) in the three quarters before Q2 2026.